|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Prostate Cancer Treatment and Commercial Issues
Datamonitor, Sep 2004, Pages: 292
Prostate cancer is the most common male malignancy in Western countries.
Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market.
This report details physician opinion of currently available products and disease management practice and what they require in the future.
Scope:
Quantitative treatment data from over 440 physicians: 60 from Japan, France, Germany, Italy, Spain and the UK, and 80 from the US
Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects
Analysis of leading companies in the prostate cancer market and the commercial challenges and opportunities ahead.
Highlights:
AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists.
In Japan the volume usage of hormonal drug therapy is far more common as the average age of the patient is well over 70 and so curative treatment is often contraindicated. We believe the high volume usage of hormonal therapies makes this an important country in which to market effective, low toxicity drugs.
Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis Taxotere show much greater efficacy and usage of this combination is already significant.
Reasons to Purchase:
Identify hot topics and key issues for practicing prostate cancer specialists the questions they really want answered
Predict future trends in the treatment of prostate cancer and how to capitalize on forthcoming changes in treatment practice
Plan product development to fill prostate cancer market niches as defined by practicing physicians
Customers who bought this item also bought
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Stakeholder Insight: Prostate Cancer Treatment in the USA
Prostate Cancer Insight - Profiting From Changing Treatment Patterns
Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter
Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer
Treatment Algorithms 2001: Prostate Cancer
Stakeholder Insight: Local and Locally Advanced Prostate Cancer
Prostate Cancer Therapeutics - Global Strategic Business Report
Prostate Cancer - A Prostrate Market Waiting For Innovations
Bisphosphonates Update - The Treatment and Prevention of Bone Metastases in Breast and Prostate Cancer
Chinese Markets for Prostate Cancer Treatment Drugs
Antibody Drug Targets and Focus on Breast & Prostate Cancer
|
|
|
|
